Personalized treatment to help people with cancer quit smoking and live longer
Official title: Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients
Run by Washington University School of Medicine · NCT07166120 · Data updated 2026-11-12
We will test whether personalized tobacco treatment using clinical, genetic, and biomarker information helps cancer patients who smoke quit and use cessation medications more than usual care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 89 Years |
| Sex | All |
| Enrollment | 132 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 2 sites (St Louis, Missouri and 1 other locations) |
| Status | Recruiting |
| Started | September 11, 2025 |
| Main results expected | March 31, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT07166120 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult oncology clinic patients aged 18 to 89 who currently smoke about five or more cigarettes per day, can speak English, and are willing to consider medication to help reduce craving or smoking.
✕Probably not a fit
People already using smoking-cessation medication, those with contraindications to combination nicotine replacement therapy or varenicline (including pregnancy or certain cardiac problems), non-English speakers, or those unwilling to try medications may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multilevel precision tobacco treatment program (PrecisionTx-Onc) that gives personalized risk, benefit, and medication recommendations to clinicians and patients using clinical, genetic, and biomarker data. The intervention is compared to usual care in a 2-arm cluster randomized trial of 16 clinicians and about 96 patients (roughly six patients per clinician) with 1:1 allocation. Primary outcomes include patient receipt of tobacco treatment, medication use, and smoking abstinence measured at six months, along with mechanistic and implementation outcomes. The study is embedded in oncology/hematology clinics and was developed with input from both patients and providers.
Why it matters
Potential benefit: If successful, patients could get better-matched cessation medications and more clinician support, increasing quit rates and potentially improving survival.
How similar studies have gone: Some prior work suggests precision-guided smoking treatments can improve medication matching and quit outcomes, but applying a multilevel precision intervention specifically in oncology clinics is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Eligibility Criteria for Clinicians: * Clinician from participating oncology/hematology clinic * At least 18 years of age * Can speak and understand English Inclusion Criteria for Patients: * Patient at participating clinic * Age 18-89 years * Current smoking (average cigarettes per day ≥5) * Can speak and understand English * Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline Exclusion Criteria for Patients: * Active use of smoking cessation medication (within the past 30 days) * Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days) * Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy) * Patients who were deemed by the investigator to be ineligible for participation in the trial
Where it's running
-
John Cochran Veteran's Affairs Medical Center
St Louis, Missouri, United States Recruiting -
Washington University School of Medicine
St Louis, Missouri, United States Recruiting
Study contacts
- Principal investigator: Li-Shiun Chen, ScD, M.D., MPH — Washington University School of Medicine
- Study coordinator: Li-Shiun Chen, ScD, M.D., MPH
- Email: li-shiun@wustl.edu
- Phone: 314-362-3932
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized treatment for smoking cessation in primary care
This study is testing a personalized approach to help people quit smoking in primary care to see if it works better than the usual methods.
-
Actívatexto: Helping Latinos quit smoking and become more active
This trial tests whether Actívatexto, a text-message program combined with wearables and nicotine replacement, helps Latino adults who smoke quit and increase their physical activity.
-
Quitting Matters: a smoking quit program for people living with HIV
This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.
-
Technology-based motivational interviewing to help adults quit smoking
This project will try a chatbot-based motivational interviewing coach to help adult primary care patients who smoke become ready to quit and create a personalized quit plan.
-
Using an air quality monitor to encourage smoke-free homes for cancer patients
This study is testing if using an air quality monitor can help cancer patients who smoke create smoke-free homes and quit smoking.
-
Proactive tobacco treatment for household smokers through pediatric care
This study is testing a new way to help household smokers quit tobacco by using support from pediatric care to see if it can improve their chances of success.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.